BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by Geneva Capital Management LLC

Geneva Capital Management LLC lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 880,215 shares of the medical equipment provider’s stock after purchasing an additional 5,730 shares during the period. Geneva Capital Management LLC owned 1.94% of BioLife Solutions worth $16,328,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Goldman Sachs Group Inc. raised its position in shares of BioLife Solutions by 1,038.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,401,899 shares of the medical equipment provider’s stock valued at $39,031,000 after buying an additional 2,191,002 shares during the period. Granahan Investment Management LLC increased its position in shares of BioLife Solutions by 22.8% during the fourth quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider’s stock worth $21,006,000 after acquiring an additional 240,001 shares during the period. Roubaix Capital LLC increased its position in shares of BioLife Solutions by 90.8% during the fourth quarter. Roubaix Capital LLC now owns 280,337 shares of the medical equipment provider’s stock worth $4,555,000 after acquiring an additional 133,439 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of BioLife Solutions by 161,879.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 131,203 shares of the medical equipment provider’s stock worth $2,434,000 after acquiring an additional 131,122 shares during the period. Finally, Millrace Asset Group Inc. increased its position in shares of BioLife Solutions by 116.0% during the fourth quarter. Millrace Asset Group Inc. now owns 105,643 shares of the medical equipment provider’s stock worth $1,717,000 after acquiring an additional 56,726 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Stock Performance

Shares of BLFS stock traded up $1.66 during mid-day trading on Thursday, hitting $20.97. 623,668 shares of the stock were exchanged, compared to its average volume of 400,180. The stock’s fifty day simple moving average is $20.68 and its two-hundred day simple moving average is $18.49. The stock has a market capitalization of $966.09 million, a price-to-earnings ratio of -14.59 and a beta of 1.85. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $23.32. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.77 and a current ratio of 2.89.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06. The company had revenue of $31.73 million for the quarter, compared to analyst estimates of $29.30 million. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. During the same quarter last year, the company posted ($0.27) earnings per share. On average, analysts forecast that BioLife Solutions, Inc. will post -0.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BLFS shares. Jefferies Financial Group assumed coverage on BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price objective on the stock. Benchmark upgraded shares of BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Monday, May 13th. Finally, StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Insiders Place Their Bets

In related news, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $20.18, for a total transaction of $201,800.00. Following the transaction, the chief marketing officer now owns 108,894 shares of the company’s stock, valued at $2,197,480.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $20.18, for a total transaction of $201,800.00. Following the transaction, the chief marketing officer now owns 108,894 shares of the company’s stock, valued at $2,197,480.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sarah Aebersold sold 3,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the completion of the sale, the insider now owns 61,683 shares of the company’s stock, valued at approximately $1,297,193.49. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,845 shares of company stock valued at $510,734. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.